Cellectar Biosciences to Host Conference Call on May 14th to Discuss First Quarter 2014 Results and Provide Quarterly Update on Development Progress May 12, 2014
Cellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug Administration May 5, 2014
Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress Mar 19, 2014
Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Mar 4, 2014
CORRECTING and REPLACING -- Novelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc. Feb 11, 2014